Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens.
暂无分享,去创建一个
R. Kinders | Robert J Kinders | Andrea Regier Voth | A. Voth | Deborah Wilsker | Scott Lawrence | D. Wilsker | Allison Marrero | S. Lawrence | Allison M. Marrero
[1] E. Kohn,et al. Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays , 2007, Proteomics.
[2] E. Sausville,et al. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.
[3] D. Rimm,et al. Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.
[4] D. Rimm,et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Kutok,et al. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis , 2015, Leukemia & lymphoma.
[6] Marcus Oswald,et al. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery. , 2014, Biochimica et biophysica acta.
[7] D. Rimm,et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. , 2005, Journal of the National Cancer Institute.
[8] Yiling Lu,et al. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. , 2016, Seminars in oncology.
[9] J. Soria,et al. Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma , 2013, Clinical Cancer Research.
[10] Larry Rubinstein,et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Yvonne A. Evrard,et al. Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity , 2010, Clinical Cancer Research.
[12] K. Baggerly,et al. Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia , 2014, Clinical Cancer Research.
[13] D. Chan,et al. Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[14] Nianxiang Zhang,et al. Reverse-Phase Protein Array Analysis to Identify Biomarker Proteins in Human Pancreatic Cancer , 2013, Digestive Diseases and Sciences.
[15] Jingchun Zhu,et al. Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report , 2014, Molecular & Cellular Proteomics.
[16] Olivier Sordet,et al. γ-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin. , 2011, Methods in molecular biology.
[17] W. Böcker,et al. Complex H2AX phosphorylation patterns by multiple kinases including ATM and DNA‐PK in human cells exposed to ionizing radiation and treated with kinase inhibitors , 2005, Journal of cellular physiology.
[18] H. Höfler,et al. Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer , 2014, British Journal of Cancer.
[19] J. Doroshow,et al. Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors. , 2014 .
[20] C. Bassing,et al. ATR and H2AX Cooperate in Maintaining Genome Stability under Replication Stress* , 2009, Journal of Biological Chemistry.
[21] R. Parchment,et al. Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations , 2014, Clinical Cancer Research.
[22] J. J. Macklin,et al. A general method to improve fluorophores for live-cell and single-molecule microscopy , 2014, Nature Methods.
[23] M. Braun,et al. Spheroid formation of human thyroid cancer cells under simulated microgravity: a possible role of CTGF and CAV1 , 2014, Cell Communication and Signaling.
[24] D. Esposito,et al. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use , 2015, Clinical Cancer Research.
[25] L. Rubinstein,et al. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts , 2008, Clinical Cancer Research.
[26] Ioan Tabus,et al. Analysis of signaling pathways in 90 cancer cell lines by protein lysate array. , 2007, Journal of proteome research.
[27] P. Bonate,et al. Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer , 2013, PloS one.
[28] E. Sausville,et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] George G Klee,et al. Measurement and quality control issues in multiplex protein assays: a case study. , 2009, Clinical chemistry.
[30] Jean W Lee,et al. Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics. , 2009, Bioanalysis.
[31] U. Olsson‐Strömberg,et al. The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses , 2015, Molecular Cancer Therapeutics.
[32] K. Giese,et al. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] L. True,et al. Impact of Preanalytic Factors on the Design and Application of Integral Biomarkers for Directing Patient Therapy , 2012, Clinical Cancer Research.